Skip to main content
. 2018 Oct 17;10(10):387. doi: 10.3390/cancers10100387

Figure 2.

Figure 2

Time-line of HACA development during treatment with ch14.18/CHO. Serum samples collected from 122 pts treated with up to five cycles of ch14.18/CHO immunotherapy were analyzed in every cycle with a validated ELISA allowing for the detection of anti-ch14.18/CHO Abs (HACA). The cumulative incidence of HACA in treated pts during the treatment period is shown over time (black solid line). For a better overview, the end of the respective cycle is indicated by dashed vertical lines.